RELAPSED NON-HODGKIN LYMPHOMA

This is a first-in-human study testing a new type of personalized cell therapy called CD79b-19 CAR T cells for adults with Non-Hodgkin Lymphoma that has come back or not responded to prior treatments. The main goal is to find a safe dose of these modified immune cells, which are …

This is a first-in-human study testing the safety and early effectiveness of a new, single-infusion CAR-T cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T …

This study is testing whether combining an existing immunotherapy drug (pembrolizumab) with a vitamin A-based drug (ATRA) can help control lymphoma that has come back or stopped responding to standard treatments. It will enroll 24 adults with specific types of Hodgkin or B-cell n…

This study is testing a two-step treatment for patients with large B-cell lymphoma that has come back or hasn't responded to other treatments. First, patients receive targeted radiation to all visible cancer sites to shrink large tumors. Then, they receive a personalized immune c…

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This study is testing a personalized treatment called CAR T-cell therapy for people with aggressive lymphoma or acute lymphoblastic leukemia that has returned or not responded to standard treatments. Doctors collect a patient's own immune cells, genetically modify them in a lab t…

This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma that has returned or not responded to standard therapies. It will give 22 patients a three-part regimen: first a personalized cell therapy (CAR-T), followed by two other drugs. The main goal is …

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…